Member Info for ontarget

Looks like this licence might be approved sooner than we think.

Really?

My this is looking shiite. Anyone know if Dr Sandler is in the office today?

Thanks for the clarification.

Ok I guess this is the new one, other one is for a different district

https://mali.revenuedev.org/application/159525

Not up to date here but isn't this KOD's mining licence?

https://mali.revenuedev.org/license/144936

Says 'Active Licence', so does this mean it's already been granted?

I for one am glad HEMO haven't jumped on this bandwagon. Incredibly risky as once one company does come out with a vaccine or the virus fizzles out of its own accord the game's over.

Possible if you hold a few 100k perhaps, but not with 3-4m.

Regarding CAR-T linking into Globalco - nothing announced to this effect so far but I would guess they might want to include the CAR-T in any in-licencing agreement and potentially combine the trials. This of course will mean lots more $$$ for HEMO.

In my opinion globalco financing/in-licencing news has to come very soon. We know HEMO doesn't have the cash to fund the monkey trials which I assume will have to be started (and finished) well before the pre-IND meeting which is supposedly to happen by August. The placing RNS said most of the cash raised was to be spent on non-CDX projects apart from working capital. We know that the globalco will fund it, but the company have yet to announce such a funding agreement, which surely they must do as it is very material?

Orgenesis (NASDAQ:ORGS) the company that previously invested $1m into Hemogenyx-Cell, the subsidiary working on Hu-PHEC, have just received $130m cash from the sale of one of their subsidiaries.

In a news release on Friday ORGS said

"Orgenesis expects to use the net proceeds from the Sale to continue to grow its point-of-care cell therapy business and to further the development of Advanced Therapy Medicinal Products."

There must be a good chance ORGS will seek to 'top-up' a few of its investments in the cell therapy area, or maybe even buy a few outright?

The previous investment in Hemogenyx-Cell was at a valuation of $12m, so perhaps $15m-20m and a small royalty would be acceptable to buy the whole subsidiary? I note there was no mention at all of Hu-PHEC in the recent funding announcement, nor any mention of its current status or HEMO's plans for it in the patent news last week when there was the perfect opportunity to do so.

Any thoughts?

Might just be the MM's exploring supply/demand. They were offering stock at ~1.85 earlier but now 1.97 minimum with no apparent trades in between.

Not sure, but they said on twitter this was the first in a series.

Did no-one else find the sound awful on that video? Sounded like a fan was going off the whole time which made the speaking very difficult to hear. Hope they sort it out for the next one.

Well the RNS told us what the funds would be used for at it was mainly the 'other' stuff in the portfolio rather than the core CDX. We are yet to hear how they are going to pay for those monkey trials and beyond, and indeed when they are going to happen.

Video now works, looks like the date was a mistake. Maybe the date for the next instalment?

https://youtu.be/omgI3JzdSVQ

Moving on with its portfolio is all very well but as ever we need progress on the CDX collaboration and in particular news on that. Clearer timelines for that would be appreciated.

Wonder why it can't be seen until 17th?
Something mentioned that needs to be announced first??

Is anyone else having issues with this site today? It keeps logging me out, can't view level 2 etc?

Always good to see directors putting their hands in their pockets, especially the finance guy.
Only £5k but still not to be sniffed at.